Innate Pharma (XPAR:IPH) FCF Yield % : -19.72 (As of May. 04, 2024)

View and export this data going back to 2006. Start your Free Trial

What is Innate Pharma FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Innate Pharma's Trailing 12-Month Free Cash Flow is €-34.91 Mil, and Market Cap is €178.26 Mil. Therefore, Innate Pharma's FCF Yield % for today is -19.72%.

The historical rank and industry rank for Innate Pharma's FCF Yield % or its related term are showing as below:

XPAR:IPH' s FCF Yield % Range Over the Past 10 Years
Min: -37.21 Med: -9.34 Max: 38.08
Current: -19.72

During the past 13 years, the highest FCF Yield % of Innate Pharma was 38.08%. The lowest was -37.21%. And the median was -9.34%.

XPAR:IPH's FCF Yield % is ranked worse than
57.82% of 1553 companies
in the Biotechnology industry
Industry Median: -14.39 vs XPAR:IPH: -19.72

Innate Pharma's FCF Margin % for the quarter that ended in Dec. 2023 was -139.73%.

Innate Pharma FCF Yield % Historical Data

The historical data trend for Innate Pharma's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innate Pharma FCF Yield % Chart

Innate Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Yield %

Get a 7-Day Free Trial

-6.49

-23.06

-16.90

-7.75

-16.48

Innate Pharma Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Yield %	Get a 7-Day Free Trial															-16.03	0.78	-16.11	-10.17	-21.85

Competitive Comparison of Innate Pharma's FCF Yield %

For the Biotechnology subindustry, Innate Pharma's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innate Pharma's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innate Pharma's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Innate Pharma's FCF Yield % falls into.

Innate Pharma FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Innate Pharma's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-34.909	/	211.80604
	=	-16.48%

Innate Pharma's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-23.135	*	2	/	211.80604
	=	-21.85%

Innate Pharma FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Innate Pharma FCF Yield % Related Terms

Thank you for viewing the detailed overview of Innate Pharma's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Innate Pharma (XPAR:IPH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (XPAR:IPH) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

IPHYF:USA IPHA:USA 0EVI:UK IDDA:Germany

Address

117, Avenue de Luminy, Marseille, FRA, 13009

Website

https://www.innate-pharma.com

Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, avdoralimab, and others.

Innate Pharma (XPAR:IPH) Headlines

No Headlines